• Services
    • Infusion Management Services Navigation Header
      • Infusion Management Services
    • Ambulatory Infusion Centers Header
      • Ambulatory Infusion Centers
    • Pharmacy Services Navigation Header
      • Pharmacy Services
    • Wholesale Distribution Navigation Header
      • Wholesale Distribution
    • Clinical Outcomes Research Navigation Header
      • Clinical Outcomes Research
    • Outsourced Patient Support and Hub Services Navigation Header
      • Outsourced Patient Support and Hub Services
  • Company
    • About Us
    • News & Events
    • History of Infusion
  • Careers
  • Contact Us
  • Contact Us
  • Services
    • Infusion Management Services
    • Ambulatory Infusion Centers
    • Pharmacy Services
    • Wholesale Distribution
    • Clinical Outcomes Research
    • Outsourced Patient Support and Hub Services
  • Company
    • About Us
    • News & Events
    • History of Infusion
  • Careers

Immune Globulin Subcutaneous 16.5% in the Treatment of Primary Immunodeficiency: A Two-Year Multicenter Analysis

Feb 24, 2024 | Clinical Outcomes

Presented at AAAAI 2024 Authors: Richard F. Herrscher, MD, FACAAI Jeffrey W. Langford, MD, AE-C Precious A. Anyanwu, PharmD, PhD Lucinda J. Van Anglen, PharmD View Poster

Real-World Outcomes with Subcutaneous Immunoglobulin 16.5% in the Treatment of Primary Immunodeficiency

Oct 8, 2023 | Clinical Outcomes

Presented at IgNS 2023 Authors: Lucinda J. Van Anglen, PharmD Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Precious A. Anyanwu, PharmD, PhD View Poster

Real-World Outcomes After Switching to Immune Globulin Subcutaneous 16.5% In Patients with Primary Humoral Immunodeficiency: A 3-Year Study

Feb 25, 2023 | Clinical Outcomes

Presented at AAAAI 2023 Authors: Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Dawn N. Kim-Romo, PharmD, PhD, MS Lucinda J. Van Anglen, PharmD View Poster

Treatment With Intravenous Immune Globulin 10% In A Real-World Outpatient Setting

Feb 25, 2023 | Clinical Outcomes

Presented at AAAAI 2023 Authors: Richard F. Herrscher, MD, FACAAI Kevin Rosenbach, MD Quyen Luu, MD Dawn N. Kim-Romo, PharmD, PhD, MS Lucinda J. Van Anglen, PharmD View Poster

Long-Term Outcomes with Immune Globulin Subcutaneous 16.5% in Treatment of Primary Immunodeficiency

Nov 12, 2023 | Clinical Outcomes

Presented at ACAAI 2023 Authors: Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Precious A. Anyanwu, PharmD, PhD Lucinda J. Van Anglen, PharmD View Poster

Epstein-Barr Virus Associated Ulcers in a Patient with Ulcerative Colitis Taking Vedolizumab: A Case Report

Oct 23, 2023 | Clinical Outcomes

Presented at ACG 2023 Authors: Christopher Fernandes, BSc Christine Catinis, MS, MD Precious Anyanwu, PharmD, PhD, Timothy E Ritter, MD View Poster  View Abstract
Page 3 of 11«12345...10...»Last »

Recent Posts

  • Evaluation of Fecal Microbiota, Live-jslm by Standard of Care Antibiotic Washout Period for the Prevention of Recurrent Clostridioides difficile Infection
  • Efficacy and Safety of Rezafungin, A Long-Acting Echinocandin
  • Real-World Effectiveness and Health-Related Quality of Life Improvements Using Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection
  • Long-term Effectiveness of Long-Acting Cabotegravir and Rilpivirine in an Infectious Disease Office-Based HIV Program
  • Meet the Healix Team at IDWeek 2025

Recent Comments

    Archives

    • October 2025
    • September 2025
    • June 2025
    • April 2025
    • March 2025
    • February 2025
    • December 2024
    • October 2024
    • August 2024
    • May 2024
    • April 2024
    • February 2024
    • November 2023
    • October 2023
    • June 2023
    • February 2023
    • January 2023
    • November 2022
    • October 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • November 2021
    • October 2021
    • September 2021
    • November 2020
    • October 2020
    • July 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • October 2019
    • August 2019
    • July 2019
    • May 2019
    • April 2019
    • February 2019
    • December 2018
    • October 2018
    • July 2018
    • June 2018
    • January 2018
    • December 2017
    • October 2017
    • July 2017
    • June 2017
    • March 2017
    • October 2016
    • June 2016
    • January 2016
    • October 2015
    • December 2014
    • October 2014
    • November 2013
    • October 2013
    • July 2013
    • February 2013
    • January 2013
    • December 2012
    • November 2012
    • October 2012
    • April 2012
    • February 2012
    • January 2012
    • October 2011
    • January 2011
    • October 2010
    • October 2009
    • October 2008

    Categories

    • Blog
    • Clinical Outcomes
    • Cost Savings
    • Events
    • Infusion Management Services
    • New Therapies & Programs
    • News
    • Persistence
    • Services
    • Special Populations

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Follow
    • Follow
    • Follow
    • Contact Us
    • Careers
    • Terms and Conditions
    • Privacy Policy
    • Client Login

    2150 Town Square Place Suite 395, Sugar Land, TX  77479
    (800)-422-2204

    © Healix Infusion Therapy